This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cusack, J. C. Articles by Palladino, M. A. Search for Related Content PubMed PubMed Citation Articles by Cusack, J. C., Jr. Articles by Palladino, M. A.

NPI-0052 Enhances Tumoricidal Response to Conventional Cancer Therapy in a Colon Cancer Model

Authors' Affiliations: ¹ Division of Surgical Oncology, Massachusetts General Hospital; ² Harvard Medical School, Boston, Massachusetts; and ³ Nereus Pharmaceuticals, San Diego, California

Requests for reprints: James C. Cusack, Jr., Division of Surgical Oncology, Massachusetts General Hospital, Yawkey 7th Floor, 55 Fruit Street, Boston, MA 02114. Phone: 617-724-4093; Fax: 617-724-3895; E-mail: jcusack{at}partners.org.

Purpose: In the current study, we examine the effects of a novel proteasome inhibitor, NPI-0052 (salinosporamide A), on proteasome function and nuclear factor-B activation and evaluate its ability to enhance treatment response in colon cancer xenografts when administered orally.

Experimental Design: The effects of treatment on nuclear factor-B activation, cell cycle regulation, and apoptosis were determined. The pharmacodynamic effect of NPI-0052 on 20S proteasome function was assayed in vivo following oral and i.v. drug administration and compared with treatment with bortezomib. The effect of combined treatment with chemotherapy was determined in a colon cancer xenograft model.

Results: We found that NPI-0052 is a potent, well-tolerated proteasome inhibitor that has pharmacodynamic properties distinct from bortezomib in that it achieves significantly higher and more sustained levels of proteasome inhibition. When combined with chemotherapy, NPI-0052 increases apoptosis and shifts cells toward G₂ cell cycle arrest. When added to chemotherapy in vivo [using combinations of 5-fluorouracil (5-FU), CPT-11, Avastin (bevacizumab), leucovorin, and oxaliplatin], NPI-0052 significantly improved the tumoricidal response and resulted in a 1.8-fold increased response to CPT-11, 5-FU, and leucovorin triple-drug combination (P = 0.0002, t test), a 1.5-fold increased response to the oxaliplatin, 5-FU, and leucovorin triple-drug combination (P = 0.013, t test), and a 2.3-fold greater response to the CPT-11, 5-FU, leucovorin, and Avastin regimen (P = 0.00057).

Conclusions: The high level of proteasome inhibition achieved by NPI-0052 is well tolerated and significantly improves the tumoricidal response to multidrug treatment in a colon cancer xenograft model. Further evaluation of this novel proteasome inhibitor in clinical trials is indicated.

This article has been cited by other articles:

				C. M. Sloss, F. Wang, R. Liu, L. Xia, M. Houston, D. Ljungman, M. A. Palladino, and J. C. Cusack Jr. Proteasome Inhibition Activates Epidermal Growth Factor Receptor (EGFR) and EGFR-Independent Mitogenic Kinase Signaling Pathways in Pancreatic Cancer Cells Clin. Cancer Res., August 15, 2008; 14(16): 5116 - 5123. [Abstract] [Full Text] [PDF]

				S. Uddin, M. Ahmed, P. Bavi, R. El-Sayed, N. Al-Sanea, A. AbdulJabbar, L. H. Ashari, S. Alhomoud, F. Al-Dayel, A. R. Hussain, et al. Bortezomib (Velcade) Induces p27Kip1 Expression through S-Phase Kinase Protein 2 Degradation in Colorectal Cancer Cancer Res., May 1, 2008; 68(9): 3379 - 3388. [Abstract] [Full Text] [PDF]

				S. Baritaki, E. Suzuki, K. Umezawa, D. A. Spandidos, J. Berenson, T. R. Daniels, M. L. Penichet, A. R. Jazirehi, M. Palladino, and B. Bonavida Inhibition of Yin Yang 1-Dependent Repressor Activity of DR5 Transcription and Expression by the Novel Proteasome Inhibitor NPI-0052 Contributes to its TRAIL-Enhanced Apoptosis in Cancer Cells J. Immunol., May 1, 2008; 180(9): 6199 - 6210. [Abstract] [Full Text] [PDF]

				D. Chauhan, A. Singh, M. Brahmandam, K. Podar, T. Hideshima, P. Richardson, N. Munshi, M. A. Palladino, and K. C. Anderson Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma Blood, February 1, 2008; 111(3): 1654 - 1664. [Abstract] [Full Text] [PDF]

				K. S. Ahn, G. Sethi, T.-H. Chao, S. T. C. Neuteboom, M. M. Chaturvedi, M. A. Palladino, A. Younes, and B. B. Aggarwal Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-{kappa}B regulated gene products Blood, October 1, 2007; 110(7): 2286 - 2295. [Abstract] [Full Text] [PDF]

				S. D. Demo, C. J. Kirk, M. A. Aujay, T. J. Buchholz, M. Dajee, M. N. Ho, J. Jiang, G. J. Laidig, E. R. Lewis, F. Parlati, et al. Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome Cancer Res., July 1, 2007; 67(13): 6383 - 6391. [Abstract] [Full Text] [PDF]

				C. Marx, C. Yau, S. Banwait, Y. Zhou, G. K. Scott, B. Hann, J. W. Park, and C. C. Benz Proteasome-Regulated ERBB2 and Estrogen Receptor Pathways in Breast Cancer Mol. Pharmacol., June 1, 2007; 71(6): 1525 - 1534. [Abstract] [Full Text] [PDF]